Literature DB >> 12046877

Bioptics in phakic and pseudophakic intraocular lens with the Nidek EC-5000 excimer laser.

Roberto Zaldivar1, Susana Oscherow, Virginia Piezzi.   

Abstract

PURPOSE: To evaluate predictability, safety, stability, and complications related to bioptics in patients that received phakic and those that received pseudophakic intraocular lenses. Both groups had LASIK with the Nidek EC-5000 excimer laser following IOL implantation.
METHODS: We evaluated retrospectively 281 eyes of 196 patients with posterior chamber phakic implantation (ICL) and 64 pseudophakic eyes of 55 patients. All patients had LASIK 1 month or more after the first surgery. We used a treatment zone of 5.5 mm with a 7.00-mm transition zone. The flap was made with the Automated Corneal Shaper (ACS).
RESULTS: In the group of phakic ICL eyes with bioptics, preoperative mean spherical equivalent refraction was -5.50 D (range, -1.37 to -16.00 D). The first day after LASIK, mean spherical equivalent refraction was -0.06 D, and at 1 month, -0.40 D. In pseudophakic bioptics eyes, preoperative mean spherical equivalent refraction was -2.61 D (range, +0.50 to -5.50 D). The first day after LASIK it was +0.27 D, and 1 month after LASIK it was +0.09 D. The incidence of complications was similar in both groups of patients. The most frequent complication was keratitis sicca (approximately 10% in each group). Interstitial edema (2.1%) was present only in phakic bioptics eyes. No retinal complications were observed. Refraction was stable 4 years after surgery. Target achieved refraction was +/- 0.50 D, showing the predictability of the procedure.
CONCLUSIONS: Predictability and safety were demonstrated according to results and absence of severe complications related with this technique. Older patients did not develop more complications than younger people; dry eye incidence was similar in both groups. In extreme myopia patients did not present retinal complications related to surgical procedures.

Entities:  

Mesh:

Year:  2002        PMID: 12046877     DOI: 10.3928/1081-597X-20020502-10

Source DB:  PubMed          Journal:  J Refract Surg        ISSN: 1081-597X            Impact factor:   3.573


  7 in total

1.  Limbal relaxing incision during cataract extraction versus photoastigmatic keratectomy after cataract extraction in controlling pre-existing corneal astigmatism.

Authors:  Sameh Fouda; Kazutaka Kamiya; Daisuke Aizawa; Kimiya Shimizu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-02-06       Impact factor: 3.117

2.  Implantable collamer lens for residual refractive error after corneal refractive surgery.

Authors:  Xun Chen; Xiao-Ying Wang; Xi Zhang; Zhi Chen; Xing-Tao Zhou
Journal:  Int J Ophthalmol       Date:  2016-10-18       Impact factor: 1.779

3.  Outcomes of excimer laser enhancements in pseudophakic patients with multifocal intraocular lens.

Authors:  Steven C Schallhorn; Jan A Venter; David Teenan; Julie M Schallhorn; Keith A Hettinger; Stephen J Hannan; Martina Pelouskova
Journal:  Clin Ophthalmol       Date:  2016-04-27

Review 4.  Corneal-Based Surgical Presbyopic Therapies and Their Application in Pseudophakic Patients.

Authors:  Grace L Paley; Roy S Chuck; Linda M Tsai
Journal:  J Ophthalmol       Date:  2016-03-09       Impact factor: 1.909

5.  Pseudophakic ametropia management with toric implantable collamer lens with a central hole (case report).

Authors:  Xun Chen; Xiaoying Wang; Xingtao Zhou
Journal:  BMC Ophthalmol       Date:  2017-02-21       Impact factor: 2.209

6.  Off-Label Use of Phakic Intraocular Lens with a "Piggyback" Technique.

Authors:  Tadgh Schempf; Hoon C Jung
Journal:  Case Rep Ophthalmol       Date:  2018-11-21

7.  Visual Outcomes After Sequential Posterior Chamber Phakic IOL with Corneal Refractive Surgery (Bioptics) for the Treatment of Myopic Astigmatism.

Authors:  Majid Moshirfar; Robert J Thomson; William B West Jnr; Shannon E McCabe; Thomas M Sant; Margaret H Shmunes; Yasmyne C Ronquillo; Phillip C Hoopes
Journal:  Clin Ophthalmol       Date:  2020-12-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.